RPR manufacture of Forest's Levothroid lacked adequate stability data -- FDA warning letter.
RPR LEVOTHROID STABILITY TESTING PROCEDURES CITED IN WARNING LETTER sent to the company by FDA's San Juan, P.R. district office. Rhone-Poulenc Rorer has "failed to generate adequate stability data to support the 24-month expiration date assigned to...lots of Levothroid 88 mcg, 112 mcg and 137 mcg tablets manufactured and distributed [by Forest Labs] during 1993 and 1994," FDA said in its Nov. 4 warning letter. "The expiration date was not based on data from an adequate number of batches, it was based on accelerated data from a single batch of each strength," FDA charged.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth